Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty

TipRanksNov 8 20:24 · Ratings

H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 7 20:33 · Ratings

Q3 2024 Arbutus Biopharma Corp Earnings Call

Yahoo FinanceNov 7 15:07

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow JonesNov 7 08:31 · Ratings

Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5

Futu NewsNov 7 07:31 · Ratings

Express News | Arbutus Biopharma Corp Files for Mixed Shelf of up to $300 Mln - SEC Filing

BreakingsNov 7 05:54